drug

afimkibart

1 story · latest Sep 30, 2026

Status: Investigational
Codes: PF-06480605, RG6631, RO7790121, RVT-3101
Trials: 13 registered trials in coverage

Relationships

Developed by Roche

Timeline

Roche posts IMpower010 results in resected NSCLC; adds polatuzumab real-world study

Sep 30Weekly roundup, 9 itemsafimkibart atezolizumabUpdated

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.